» Articles » PMID: 16095998

Molecular Mechanisms in Gliomagenesis

Overview
Journal Adv Cancer Res
Publisher Elsevier
Specialty Oncology
Date 2005 Aug 13
PMID 16095998
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Glioma, and in particular high-grade astrocytoma termed glioblastoma multiforme (GBM), is the most common primary tumor of the brain. Primarily because of its diffuse nature, there is no effective treatment for GBM, and relatively little is known about the processes by which it develops. Therefore, in order to design novel therapies and treatments for GBM, research has recently intensified to identify the cellular and molecular mechanisms leading to GBM formation. Modeling of astrocytomas by genetic manipulation of mice suggests that deregulation of the pathways that control gliogenesis during normal brain development, such as the differentiation of neural stem cells (NSCs) into astrocytes, might contribute to GBM formation. These pathways include growth factor-induced signal transduction routes and processes that control cell cycle progression, such as the p16-CDK4-RB and the ARF-MDM2-p53 pathways. The expression of several of the components of these signaling cascades has been found altered in GBM, and recent data indicate that combinations of mutations in these pathways may contribute to GBM formation, although the exact mechanisms are still to be uncovered. Use of novel techniques including large-scale genomics and proteomics in combination with relevant mouse models will most likely provide novel insights into the molecular mechanisms underlying glioma formation and will hopefully lead to development of treatment modalities for GBM.

Citing Articles

Gliomagenesis, Epileptogenesis, and Remodeling of Neural Circuits: Relevance for Novel Treatment Strategies in Low- and High-Grade Gliomas.

Grimi A, Bono B, Lazzarin S, Marcheselli S, Pessina F, Riva M Int J Mol Sci. 2024; 25(16).

PMID: 39201639 PMC: 11354416. DOI: 10.3390/ijms25168953.


Advances in synthetic lethality modalities for glioblastoma multiforme.

Richard S Open Med (Wars). 2024; 19(1):20240981.

PMID: 38868315 PMC: 11167713. DOI: 10.1515/med-2024-0981.


Engineering the glioblastoma microenvironment with bioactive nanoparticles for effective immunotherapy.

Blanchard R, Adjei I RSC Adv. 2023; 13(45):31411-31425.

PMID: 37901257 PMC: 10603567. DOI: 10.1039/d3ra01153d.


Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.

Shafi O, Siddiqui G World J Surg Oncol. 2022; 20(1):146.

PMID: 35538578 PMC: 9087910. DOI: 10.1186/s12957-022-02602-5.


Aberrant expression of long non-coding RNAs (lncRNAs) is involved in brain glioma development.

Ding Y, Wang X, Pan J, Ji M, Luo Z, Zhao P Arch Med Sci. 2020; 16(1):177-188.

PMID: 32051722 PMC: 6963149. DOI: 10.5114/aoms.2020.91290.